FDA approves Journey Medical's drug for long-term skin condition (updated)

Journey Medical

04/11/2024 12:22

(Adds shares in paragraph 1, details in paragraphs 2 and 5)
       Nov 4 (Reuters) - Journey Medical  DERM.O  said on
Monday the U.S. Food and Drug Administration has approved its
drug for the treatment of a long-term skin condition called
rosacea, sending the company's shares up more than 13% before
the bell.
    The oral drug, branded Emrosi, was approved to treat
inflammatory lesions associated with the disease.
    Rosacea is a chronic inflammatory skin condition that causes
persistent redness and small pus-filled bumps, typically
affecting the central face area, including cheeks, forehead,
chin and neck. It mostly affects women and men in the age group
of 30 to 60 years.
    The condition affects more than 16 million Americans,
according to the American Academy of Dermatology Association.
    Emrosi will be commercially available to U.S. patients late
in the first quarter or early in the second quarter of 2025, the
company said.    

 (Reporting by Sruthi Narasimha Chari, Puyaan Singh and Mariam
Sunny in Bengaluru; editing by Alan Barona and Shilpi Majumdar)
 ((mailto:SruthiNarasimha.Chari@thomsonreuters.com;
mailto:puyaan.singh@thomsonreuters.com))